Business
Real-World Evidence of NEFECON® to Be Presented in Seven New Abstracts at the 18th International lgAN Symposium
At the 18th International lgA Nephropathy Symposium (IIgANN 2025), 7 new abstracts based on real-world evidence of NEFECON® will be presented. The 18th IIgANN will take place in Prague, Czech Republic, from September 17 to 20, 2025.
About this update from Everest Medicines Ltd.
[{"type":"list","items":[{"val":[{"type":"text","content":"7 new NEFECON® real-world evidence abstracts will be presented at the 18th International lgA Nephropathy Symposium (IIgANN 2025).","length":144,"tagName":"p"}]},{"val":[{"type":"text","content":"The newly released results, based on clinical practices at several leading hospitals in China, offer a comprehensive overview of the efficacy and safety of NEFECON® in the treatment of IgA nephropathy (IgAN). NEFECON® clinical value was highlighted across three key dimensions, consistent with the new disease management strategy of "Treat the cause, Treat early, Treat long-term."","length":401,"tagName":"p"}]},{"val":[{"type":"text","content":"NEFECON® is currently the only etiological treatment for IgAN recommended by both domestic and international guidelines, reinforcing its position as the foundational first-line cornerstone treatment for IgAN patients.","length":217,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":762,"olType":false},{"type":"text","content":"SHANGHAI, Sept. 15, 2025 /PRNewswire/ -- At the 18th International lgA Nephropathy Symposium (IIgANN 2025), 7 new abstracts based on real-world evidence of NEFECON® will be presented. The 18th IIgANN will take place in Prague, Czech Republic, from September 17 to 20, 2025.","length":288,"tagName":"p"},{"type":"text","content":"The newly released results, based on clinical practices at several leading hospitals in China, offer a comprehensive overview of the efficacy and safety of NEFECON® in the treatment of IgA nephropathy (IgAN). The clinical value of NEFECON® was highlighted across three key dimensions, consistent with the new disease management strategy of "Treat the cause, Treat early, Treat long-term." In real-world clinical practice, there is strong validation of NEFECON®'s value as an etiological treatment, where early intervention is critical in reducing proteinuria and protecting renal function, and extended treatment beyond 9 months provided robust evidence supporting sustained efficacy and safety.","length":719,"tagName":"p"},{"type":"text","content":"These real-world evidence not only address the limitations of randomized controlled trials (RCTs) in clinical practice but also reinforce the new disease management strategy of "Treat the cause, Tr...